Tempest Therapeutics Inc
Change company Symbol lookup
Select an option...
TPST Tempest Therapeutics Inc
PETV PetVivo Holdings Inc
KMI Kinder Morgan Inc
NXPL NextPlat Corp
D Dominion Energy Inc
CVS CVS Health Corp
CVI CVR Energy Inc
CTRE CareTrust REIT Inc
CSWC Capital Southwest Corp
CSCO Cisco Systems Inc
Go

Tempest Therapeutics, Inc. (Tempest) is a clinical-stage oncology company. The Company is focused on developing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a range of tumors. The Company’s two clinical programs include TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPARa). TPST-1120 is in Phase I and II trials in solid tumors, including a global randomized Phase Ib/II trial in combination with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, and is in Phase I monotherapy and combination trials in solid tumors.

Closing Price: $1.85

Day's Change: -0.20 (-9.76%)

Bid: --

Ask: --

B/A Size: --

Day's High: 2.04

Day's Low: 1.76

Volume (Heavy Day) Volume: 142,808 10-day average volume: 64,949: 142,808

MetLife Inc. Stock Outperforms Market Despite Losses On The Day

5:12 pm ET February 28, 2023 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of MetLife Inc. (MET) slipped 0.07% to $71.73 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.30% to 3,970.15 and Dow Jones Industrial Average falling 0.71% to 32,656.70. This was the stock's second consecutive day of losses. MetLife Inc. closed $5.63 below its 52-week high ($77.36), which the company reached on November 25th.

Trading volume (3.6 M) remained 202,015 below its 50-day average volume of 3.8 M.

Data source: Dow Jones Market Data, FactSet. Data compiled February 28, 2023.

(END) Dow Jones Newswires

February 28, 2023 17:12 ET (22:12 GMT)

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and